tetano
Editor, Senior Moderator
Vaccine. 2014 Sep 12. pii: S0264-410X(14)01235-3. doi: 10.1016/j.vaccine.2014.09.003. [Epub ahead of print]
Vaccination recommendations for patients with neuromuscular disease.
Esposito S1, Bruno C2, Berardinelli A3, Filosto M4, Mongini T5, Morandi L6, Musumeci O7, Pegoraro E8, Siciliano G9, Tonin P10, Marrosu G11, Minetti C12, Servida M13, Fiorillo C14, Conforti G15, Scapolan S15, Ansaldi F16, Vianello A17, Castaldi S18, Principi N19, Toscano A7, Moggio M13.
Author information
Abstract
Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Chronic disease; Immunocompromised patients; Influenza vaccination; Neurologic disease; Neuromuscular disease; Pneumococcal vaccine
PMID:
25223270
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25223270
Vaccination recommendations for patients with neuromuscular disease.
Esposito S1, Bruno C2, Berardinelli A3, Filosto M4, Mongini T5, Morandi L6, Musumeci O7, Pegoraro E8, Siciliano G9, Tonin P10, Marrosu G11, Minetti C12, Servida M13, Fiorillo C14, Conforti G15, Scapolan S15, Ansaldi F16, Vianello A17, Castaldi S18, Principi N19, Toscano A7, Moggio M13.
Author information
Abstract
Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated the immunogenicity, safety, tolerability, and efficacy of different vaccines in NMD patients; therefore, detailed vaccination recommendations for NMD patients are not available. Here, we present vaccination recommendations from a group of Italian Scientific Societies for optimal disease prevention in NMD patients that maintain high safety levels. We found that NMD patients can be classified into two groups according to immune function: patients with normal immunity and patients who are immunocompromised, including those who intermittently or continuously take immunosuppressive therapy. Patients with normal immunity and do not take immunosuppressive therapy can be vaccinated as healthy subjects. In contrast, immunocompromised patients, including those who take immunosuppressive therapy, should receive all inactivated vaccines as well as influenza and pneumococcal vaccines; these patients should not be administered live attenuated vaccines. In all cases, the efficacy and long-term persistence of immunity from vaccination in NMD patients can be lower than in normal subjects. Household contacts of immunocompromised NMD patients should also be vaccinated appropriately.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Chronic disease; Immunocompromised patients; Influenza vaccination; Neurologic disease; Neuromuscular disease; Pneumococcal vaccine
PMID:
25223270
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25223270